Allogene Therapeutics’ Post

🔬 Innovative Breakthrough in Lupus Treatment 🔬 🚫 No Lymphodepletion Required: One of the most notable aspects of this therapy is that it can be administered without the use of lymphodepletion, reducing the burden on patients, physicians, and the healthcare system. This is especially important considering the significant comorbidities associated with SLE. Exciting news from Synthekine! Their unique combination therapy, SYNCAR-001 + STK-009, has been cleared by the FDA for a clinical trial in the US to tackle systemic lupus erythematosus (SLE) and lupus nephritis (LN) without the need for lymphodepletion. This marks a significant step forward in the treatment of these challenging autoimmune diseases. 🎯 The Power of Combination Therapy: The therapy combines an autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) product with an engineered pegylated IL-2 cytokine. This innovative approach aims to drive cell engraftment and controlled cell expansion, offering a potential game-changer for patients with nonrenal SLE and LN. 🌍 Global Potential: As this therapy moves into clinical trials, it holds the promise of addressing critical segments of the patient population who face barriers to treatment. With preclinical results showing control of cell expansion and activation, there's a remarkable potential benefit for those suffering from this devastating disease. 💡 Insight: This breakthrough demonstrates the power of innovative therapies in addressing key limitations of current treatments. As we continue to explore the potential of CAR-T cell therapies, it's exciting to see advancements like these that could significantly improve the lives of patients around the world. #LupusTreatment #Synthekine #CAR-TTherapy #InnovativeTherapies #AutoimmuneDiseases #ClinicalTrials #HealthcareInnovation

Thank you to all of the providers who support us and trust BENEV Exosomes with their patients! A special shoutout to… 💧Mari De La Roca, LME (@pinskiderm) …for sharing what her experience has been like while using BENEV Exosomes! *Statements made by each provider are of their own experience and not the statements of BENEV Company Inc. #benevskinscience #benevexosomes #exosomes #exosomeregenerativecomplex #exocobio #benev+exocobio #exosometechnology *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

Many of the challenges facing CAR T-cell therapies remain unresolved. Recent advancements in engineering CAR T cells with novel functionalities like logic-gating are helping to evolve the field. Our article highlights key challenges and opportunities in CAR T-cell clinical development. Learn more. https://ow.ly/S8EK50RuJHZ

How can Beacon help you!

Watch our on-demand webinar to learn how #OrganChips provide more human-relevant insights into CAR T-cell therapy recruitment and efficacy, overcoming the challenges presented by conventional #research models: https://bit.ly/3ORLoC6

Are you navigating the complexities of preclinical and clinical trials? Let’s make it simpler together! Meet us at #ASGCT24, booth 2172, where Accelevir and Noble Life Sciences unite to accelerate your path from discovery to delivery. Dive into our full-service offerings in drug, vaccine, and medical device development, enhanced by precise cell and biomarker analytics. 🧬💡 👋 Swing by for a chat, learn more about our exciting collaboration, and enter our iPad raffle! #baltimore #ASGCT24 #cellandgene

Through the exploration of CAR T-cell therapies, significant opportunities have arisen to extend the applications of these innovative treatments and enhance accessibility, effectively addressing unmet medical requirements. Fundamental to these efforts to make CAR T-cell therapies more broadly available is the need to improve the safety, efficacy, and cost of these treatments. In this whitepaper from Premier Research, authors review the history and current landscape of CAR T-cell therapy research and development to gain insight from strategies used to increase safety and efficacy, while also lowering cost. #celltherapy #researchanddevelopment #strategies

Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg http://ow.ly/XzxC105z0m8

EXOSOME BEFORE AND AFTER CONTEST Do you have some incredible scalp transformations from using BENEV Exosomes?! From now until 12/31, we’re opening submissions for all BENEV customers to send in their favorite before and afters! Accepted entries that meet the company requirements are eligible for recognition! How To Enter: 1. Post your favorite before and afters of using our Exosomes on the scalp and tag @benevexosomes 2. DM us and fill out our media release forms and upload your images (must be at least 1 month post treatment) 3. Once your images are approved by BENEV’s clinical team and meet all of our requirements, you will receive a message letting you know the next steps! GRAND PRIZE: 1 Box of ERC+ & 1 Box of EXO Balm Contest runs until 12/31 at 5:00 pm PST! You must be a current BENEV Exosomes customer and submit all paperwork required to be eligible. Winner will be announced during the first week of January! #beforeandaftercontest #benevexosomes #exosomeresults Exosome Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

One of the hottest topics this year in the #TAVI business, the #SMART trial one-year outcomes were published recently. First findings on this RCT were controversial discussed already Be smart and post your experiences and comments here. It is worth it to exchange experiences, opinions and feedback on this important trial in TAVI when it comes to small annuli and clinical outcomes. #patientsfirst Let‘s also take the opportunity to share experiences during this year’s #EuroPCR in #Paris when it comes to clinical outcome in small annuli comparing intra- vs. supra-annular valve design #smarttrial #europcr #patientsfirst #tavi